Zimhi (Naloxone HCl) Patent Expiration, LOE Window & CMS Spending

Zimhi (Naloxone HCl) by Zmi: FDA Orange Book LOE 2041-06-14, 0 AB generics, $90K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorZmi
FDA Application & PathwayN212854 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2041-06-14
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$90K
2024 Medicare Part D Spend$5K
2024 Medicaid Spend$86K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel